PLIANT THERAPEUTICS INC (PLRX:NASDAQ)

$1.17 0.04 (3.5398%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 79

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed PLIANT THERAPEUTICS INC (PLRX:NASDAQ) News Sources

Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference

01-03-2026

marketbeat.com

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

11-03-2026

yahoo.com

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

18-03-2026

yahoo.com

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

11-05-2026

yahoo.com

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

18-04-2026

yahoo.com

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

30-04-2026

yahoo.com

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

06-05-2026

yahoo.com

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

13-07-2026

yahoo.com

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

11-08-2026

yahoo.com

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

18-08-2026

yahoo.com

PLIANT THERAPEUTICS INC (PLRX:NASDAQ) Sentiment Trend

0 25 50 75 100 85 78 79 77 65 81 80 79 84 78 01-03-2026 11-03-2026 18-03-2026 11-05-2026 18-04-2026 30-04-2026 06-05-2026 13-07-2026 11-08-2026 18-08-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

PLIANT THERAPEUTICS INC (PLRX:NASDAQ) FAQs

toggle

What is the current price of PLIANT THERAPEUTICS INC (PLRX:NASDAQ)?

The current price of PLIANT THERAPEUTICS INC (PLRX:NASDAQ) is $1.17.


toggle

PLIANT THERAPEUTICS INC (PLRX:NASDAQ) absolute price change since previous trading day?

The absolute price change of PLIANT THERAPEUTICS INC (PLRX:NASDAQ) since the previous trading day is $0.04.


toggle

PLIANT THERAPEUTICS INC (PLRX:NASDAQ) percentage price change since previous trading day?

The percentage price change of PLIANT THERAPEUTICS INC (PLRX:NASDAQ) since the previous trading day is 3.5398%.


toggle

What is the most recent average sentiment score for PLIANT THERAPEUTICS INC (PLRX:NASDAQ)?

The most recent average sentiment score for PLIANT THERAPEUTICS INC (PLRX:NASDAQ) is 79 out of 100.


toggle

What is the most recent average sentiment for PLIANT THERAPEUTICS INC (PLRX:NASDAQ)?

The most recent sentiment for PLIANT THERAPEUTICS INC (PLRX:NASDAQ) is .


SEC-8K** Filing Available For PLIANT THERAPEUTICS INC (PLRX:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.